Prolonged remission of disseminated atypical adenomatous hyperplasia under gefitinib

J Thorac Oncol. 2009 Feb;4(2):266-7. doi: 10.1097/JTO.0b013e3181952930.

Abstract

Atypical adenomatous hyperplasia (AAH) is a putative precursor of bronchioloalveolar carcinoma (BAC) and adenocarcinoma of the lung, developing from terminal respiratory unit cells. AAH and BAC lesions typically present as ground-glass opacities at spiral chest computed tomography. Epidermal growth factor receptor polysomy/mutations, conferring higher sensitivity to Gefitinib, are frequent in BAC but less common in AAH. We describe an interesting case of disseminated AAH showing a sustained remission under Gefitinib therapy.

Publication types

  • Case Reports

MeSH terms

  • Adenocarcinoma, Bronchiolo-Alveolar / drug therapy*
  • Adenocarcinoma, Bronchiolo-Alveolar / genetics
  • Adenocarcinoma, Bronchiolo-Alveolar / secondary
  • Antineoplastic Agents / therapeutic use*
  • ErbB Receptors / antagonists & inhibitors
  • ErbB Receptors / genetics
  • Female
  • Gefitinib
  • Humans
  • Hyperplasia
  • Lung / pathology*
  • Lung Neoplasms / drug therapy*
  • Lung Neoplasms / genetics
  • Lung Neoplasms / pathology
  • Middle Aged
  • Mutation / genetics
  • Polymerase Chain Reaction
  • Quinazolines / therapeutic use*
  • Remission Induction
  • Tomography, X-Ray Computed

Substances

  • Antineoplastic Agents
  • Quinazolines
  • ErbB Receptors
  • Gefitinib